DICE THERAPEUTICS, INC.

(DICE)
  Report
Real-time Estimate Cboe BZX  -  03:20 2022-08-16 pm EDT
19.90 USD   -5.40%
08/11DICE THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Recent Highlights - Form 8-K
PU
08/11Earnings Flash (DICE) DICE THERAPEUTICS Reports Q2 Loss $-0.58
MT
08/11DICE Therapeutics Reports Second Quarter 2022 Financial Results and Recent Highlights
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/10/2022 08/11/2022 08/12/2022 08/15/2022 08/16/2022 Date
20.39(c) 20.57(c) 20.14(c) 21.03(c) 19.865 Last
309 012 490 365 523 646 251 551 148 460 Volume
+4.30% +0.88% -2.09% +4.42% -5.54% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -88,8 M - -
Net cash position 2022 235 M - -
P/E ratio 2022 -9,65x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -137 M - -
Net cash position 2023 339 M - -
P/E ratio 2023 -6,51x
Yield 2023 -
Capitalization 804 M 804 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 61
Free-Float 95,9%
More Financials
Company
DICE Therapeutics, Inc., formerly Dice Molecules Holdings LLC, is a biopharmaceutical company. The Company leverages its technology platform to build a pipeline of oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. It is focused on developing oral therapeutics against targets in immunology. The Company’s platform, which it refers to as DELSCAPE, is designed to discover... 
More about the company
Ratings of DICE Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about DICE THERAPEUTICS, INC.
08/11DICE THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Recent Highlights - ..
PU
08/11Earnings Flash (DICE) DICE THERAPEUTICS Reports Q2 Loss $-0.58
MT
08/11DICE Therapeutics Reports Second Quarter 2022 Financial Results and Recent Highlights
GL
08/11DICE THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
AQ
08/11DICE Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months ..
CI
07/21Dice Therapeutics Completes Enrollment in Phase 1 Trial for Potential Psoriasis Treatme..
MT
07/21DICE THERAPEUTICS : Corporate Presentation July 2022
PU
07/21DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead ..
GL
07/21DICE Therapeutics, Inc. Announces Completion of Enrollment in Phase 1 Clinical Trial of..
CI
07/18HC Wainwright Initiates DICE Therapeutics at Buy With $40 Price Target
MT
06/28DICE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of..
AQ
06/24DICE THERAPEUTICS, INC.(NASDAQGM : DICE) dropped from Russell Microcap Growth Index
CI
06/24DICE THERAPEUTICS, INC.(NASDAQGM : DICE) dropped from Russell 3000E Growth Index
CI
06/24DICE THERAPEUTICS, INC.(NASDAQGM : DICE) dropped from Russell 3000 Growth Index
CI
06/24DICE THERAPEUTICS, INC.(NASDAQGM : DICE) dropped from Russell Small Cap Comp Growth Index
CI
More news
News in other languages on DICE THERAPEUTICS, INC.
08/11DICE Therapeutics, Inc. annonce ses résultats pour le deuxième trimestre et le semestre..
07/21DICE Therapeutics, Inc. annonce la fin du recrutement dans l'essai clinique de phase 1 ..
05/12DICE Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars..
03/28DICE Therapeutics, Inc. élargit son équipe de direction et son conseil d'administration
03/22La perte nette de DICE Therapeutics au 4e trimestre diminue
More news
Analyst Recommendations on DICE THERAPEUTICS, INC.
More recommendations
Chart DICE THERAPEUTICS, INC.
Duration : Period :
DICE Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DICE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 21,03 $
Average target price 41,25 $
Spread / Average Target 96,1%
EPS Revisions
Managers and Directors
J. Kevin Judice Chief Executive Officer & Director
Scott Robertson Chief Financial Officer
Richard H. Scheller Chairman
John Jacobsen Senior Vice President-Drug Discovery
Timothy Lu Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
DICE THERAPEUTICS, INC.-16.91%804
MODERNA, INC.-30.40%66 966
IQVIA HOLDINGS INC.-12.01%45 846
LONZA GROUP AG-25.13%44 851
SEAGEN INC.9.01%31 380
ALNYLAM PHARMACEUTICALS, INC.36.22%28 068